Treatment of FIP1L1/PDGFRA-negative hypereosinophilic syndrome with alemtuzumab, an anti-CD52 antibody

Journal of Allergy and Clinical Immunology

Volumn 123, Issue 6, 2009, Pages 1407-1408

  Wagner, Lori A ^a   Speckart, Stephen ^b   Cutter, Bruce ^b   Gleich, Gerald J ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b Department of Montana Oncology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ANTICOAGULANT AGENT; DEXAMETHASONE; DIPHENHYDRAMINE; HYDROXYUREA; IMATINIB; MEPOLIZUMAB; PREDNISONE; VINCRISTINE; WARFARIN; ANTINEOPLASTIC AGENT; CANCER ANTIBODY; CD52 ANTIGEN; CLEAVAGE AND POLYADENYLATION SPECIFICITY FACTOR; FIP1L1 PROTEIN, HUMAN; GAMMA INTERFERON; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; PIPERAZINE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PYRIMIDINE DERIVATIVE; TUMOR ANTIGEN;

ADULT; ANEMIA; ANTICOAGULATION; BONE BIOPSY; BRAIN INFARCTION; CASE REPORT; CAUSE OF DEATH; DISEASE COURSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EOSINOPHIL; EOSINOPHILIA; FEMALE; FLOW CYTOMETRY; HUMAN; HYPEREOSINOPHILIC SYNDROME; LETTER; LYMPHOCYTOPENIA; MULTIPLE MYELOMA; PLASMACYTOMA; PRIORITY JOURNAL; THROMBOEMBOLISM; TREATMENT FAILURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; GENETICS; METABOLISM; MIDDLE AGED;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, CD; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; FEMALE; GLYCOPROTEINS; HUMANS; HYPEREOSINOPHILIC SYNDROME; INTERFERON-GAMMA; MIDDLE AGED; MRNA CLEAVAGE AND POLYADENYLATION FACTORS; PIPERAZINES; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA;

EID: 67649213836     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2009.01.069     Document Type: Letter

References (9)

1. Klion A.D., Bochner B.S., and Gleich G.J. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol 117 (2006) 1292-1302
2. Roufosse F., Cogan E., and Goldman M. The hypereosinophilic syndrome revisited. Annu Rev Med 54 (2003) 169-184
3. Gleich G.J., Leiferman K.M., Pardanani A., Tefferi A., and Butterfield J.H. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 359 (2002) 1577-1578
4. Cools J., DeAngelo D.J., Gotlib J., Stover E.H., Legare R.D., Cortes J., et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348 (2003) 1201-1214
5. Rothenberg M.E., Klion A.D., Roufosse F.E., Kahn J.E., Weller P.F., Su H., et al. Treatment of patients with hypereosinophilic syndrome with mepolizumab. N Engl J Med 358 (2008) 1215-1228
6. Dumont F.J. Alemtuzumab (Millennium/Ilex). Curr Opin Investig Drugs 2 (2001) 139-160
7. Elsner J., Hochstetter R., Spiekermann K., and Kapp A. Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils. Blood 88 (1996) 4684-4693
8. Pitini V., Teti D., Arrigo C., and Righi M. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: a case report. Br J Haematol 127 (2004) 477
9. Sefcick A., Sowter D., Dasgupta E., Russell N.H., and Byrne J.L. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome. Br J Haematol 124 (2004) 558-559